Vlastníctvo manažmentu spoločnosti Financière de Tubize SA
Aká je hodnota metriky Vlastníctvo manažmentu spoločnosti Financière de Tubize SA?
Hodnota metriky Vlastníctvo manažmentu spoločnosti Financière de Tubize SA je 56.85%
Aká je definícia metriky Vlastníctvo manažmentu?
Vlastníctvo manažmentu (Insider Ownership) je pomer akcií vlastnených akcionármi v rámci firmy (vlastniaci viac než 5% spoločnosti alebo s titulom riaditeľa či vedúceho oddelenia) a všetkých vydaných akcií.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Vlastníctvo manažmentu spoločností v sektore Health Care sektor na EURONEXT v porovnaní so spoločnosťou Financière de Tubize SA
Čomu sa venuje spoločnosť Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Firmy s metrikou vlastníctvo manažmentu podobnou spoločnosti Financière de Tubize SA
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Las Vegas Sands je 56.80%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Kakatiya Cement Sugar and Industries je 56.81%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti McChip Resources je 56.82%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Laurus Labs je 56.83%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Reitmans (Canada) je 56.84%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Tecnoglass Inc je 56.85%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Financière de Tubize SA je 56.85%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Fairfax Africa je 56.86%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Conart Engineers je 56.86%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Moelis Australia je 56.86%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Western Pacific Trust je 56.87%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Crexendo je 56.88%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Helios Fairfax Partners je 56.88%